Devyser Diagnostics AB publishes quarterly report for July to September 2023
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further...
Oncology | September 7, 2022
With cancer identified as the leading cause of death in high-income countries, early identification and treatment of cancer, and potential cancer-causing genetic variants, is essential. As the second most common cancer worldwide, and the most frequently diagnosed cancer among women, breast cancer nonetheless has a high survival rate if diagnosed and treated.
Read more about the simple identification of both BRCA1 and BRCA2 genes in the whitepaper:
Next Generation Sequencing – Full gene sequencing of BRCA1 and BRCA2
“Devyser is reporting record sales growth (+50% organic growth) for the third quarter, a further...
Read More
Dear Devyser network, partners, and valued customers,
Read More
Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote...
Read More
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including...
Read More